278 research outputs found
The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision
No full textNo abstract availabl
Corrigendum to:Transfusion-transmitted malaria: a systematic review and meta-analysis (Open Forum Infectious Diseases (2019) 6:7 (ofz283) DOI: 10.1093/ofid/ofz283)
No full textOpen Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz283, https://doi.org/10.1093/ofid/ofz283 In “Transfusion-Transmitted Malaria: A Systematic Review and Meta-analysis”, Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz283, an acknowledgement was missed. More specifically, Alexander G. Mathioudakis was supported by the National Institute for Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC). This was corrected in the new version of the manuscript.</p
Early Career Members at the ERS International Congress London 2016
No full textThe @ERSTalk ECM Committee present highlights from #ERSLDN16 for Early Career Members http://ow.ly/tRYH305Owm
Foursquare & Flickr activities in 20 cities
No full text<p>10 millions flickr photos in 10 US & 10 European cities (photo_id, user_id, time_taken, GPS_coordinates, city, if available: associated venue id)</p>
<p>4.5 million checkins (anonymized user_id, venue id, local time, city)</p>
<p>400k venues (venue id, name, GPS_coordinates, city, category id)</p>
<p>Please cite our paper if you're using this data in your own work</p>
<p>@inproceedings{Thesis15,<br>author = {{Le Falher}, G\'{e}raud and Gionis, Aristides and Mathioudakis, Michael},<br>booktitle = {International AAAI Conference on Web and Social Media},<br>title = {{Where Is the Soho of Rome? Measures and Algorithms for Finding Similar Neighborhoods in Cities}},<br>url = {http://www.aaai.org/ocs/index.php/ICWSM/ICWSM15/paper/view/10514},<br>year = {2015}<br>}</p>
<p> </p
Current and Optimal Practices in Childhood Asthma Monitoring Among Multiple International Stakeholders
Get PDFFunding/Support: The Paediatric Asthma in Real Life (PeARL) monitoring survey was supported by the Respiratory Effectiveness Group. This study was supported by the Respiratory Effectiveness Group. The Respiratory Effectiveness Group has received support from AstraZeneca, Novartis, and Sanofi for continued work on PeARL. Dr Mathioudakis was supported by the National Institute of Health Research (NIHR) Manchester Biomedical Research Centre and by an NIHR Clinical Lectureship in Respiratory Medicine.Peer reviewe
Prevalence and clinical implications of respiratory viruses in asthma during stable disease state and acute attacks: protocol for a meta-analysis
No full textIntroduction: viruses are detected in over 50% of acute asthma attacks and in a notable proportion of patients with asthma during stable disease state They are associated with worse outcomes. We will conduct a series of systematic reviews and meta-analyses to quantify the prevalence and clinical burden of various respiratory viruses in stable asthma and acute asthma attacks. In addition, we will assess the viral loads of respiratory viruses during stable and acute asthma, to explore whether viral load could differentiate attacks triggered by viruses versus those where viruses are present as "innocent bystanders".Materials and methods: based on a prospectively registered protocol (PROSPERO, ID: CRD42023375108) and following standard methodology recommended by Cochrane, we will systematically search Medline/PubMed, EMBASE, the Cochrane Library and relevant conference proceedings for studies assessing the prevalence or clinical burden of respiratory viruses in asthma. Methodological rigour of the included studies will be appraised using a tool specific for prevalence studies and the Newcastle-Ottawa Scale respectively. In anticipation of significant clinical and methodological heterogeneity, we will conduct random effect meta-analyses. For evaluating the prevalence of viruses, we will perform meta-analyses of proportions using the inverse variance method, and the Freeman-Tukey transformation. We will conduct meta-regression analyses for exploring heterogeneity.Conclusion: we envisage that these systematic reviews and meta-analyses will quantify the prevalence and burden of respiratory viruses in stable and acute asthma and will drive future research and clinical practice.</p
ERS clinical practice guidelines on treatment of sarcoidosis
No full textBackground The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin or other manifestations. While glucocorticoids remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity. Glucocorticoid-sparing alternatives are available. The presented treatment guidelines aim to provide guidance to physicians treating the very heterogenous sarcoidosis manifestations. Methods A European Respiratory Society Task Force committee composed of clinicians, methodologists and patients with experience in sarcoidosis developed recommendations based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology. The committee developed eight PICO (Patients, Intervention, Comparison, Outcomes) questions and these were used to make specific evidence-based recommendations. Results The Task Force committee delivered 12 recommendations for seven PICOs. These included treatment of pulmonary, cutaneous, cardiac and neurologic disease as well as fatigue. One PICO question regarding small-fibre neuropathy had insufficient evidence to support a recommendation. In addition to the recommendations, the committee provided information on how they use alternative treatments, when there was insufficient evidence to support a recommendation. Conclusions There are many treatments available to treat sarcoidosis. Given the diverse nature of the disease, treatment decisions require an assessment of organ involvement, risk for significant morbidity, and impact on QoL of the disease and treatment.Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin or other manifestations. While glucocorticoids remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity. Glucocorticoid-sparing alternatives are available. The presented treatment guidelines aim to provide guidance to physicians treating the very heterogenous sarcoidosis manifestations. Methods A European Respiratory Society Task Force committee composed of clinicians, methodologists and patients with experience in sarcoidosis developed recommendations based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology. The committee developed eight PICO (Patients, Intervention, Comparison, Outcomes) questions and these were used to make specific evidence-based recommendations. Results The Task Force committee delivered 12 recommendations for seven PICOs. These included treatment of pulmonary, cutaneous, cardiac and neurologic disease as well as fatigue. One PICO question regarding small-fibre neuropathy had insufficient evidence to support a recommendation. In addition to the recommendations, the committee provided information on how they use alternative treatments, when there was insufficient evidence to support a recommendation. Conclusions There are many treatments available to treat sarcoidosis. Given the diverse nature of the disease, treatment decisions require an assessment of organ involvement, risk for significant morbidity, and impact on QoL of the disease and treatment
Core outcome sets, developed collaboratively with patients, can improve the relevance and comparability of clinical trials
No full textTransfusion-transmitted Malaria: A Systematic Review and Meta-Analysis
Get PDFBackground: Malaria transmission through blood transfusion is an accidental butpreventable cause of malaria infection and is increasingly becoming a matter of concern for blood transfusion services.Objectives: This systematic review was conducted to provide a summary of evidence about the prevalence of Plasmodium infection in asymptomatic blood donors and the effectiveness of screening methods used based on the available literature.Data sources: PRISMA guidelines were followed. Scopus, PubMed, Science Direct, and EMBASE were searched from 1982 to 10th of October 2017.Study eligibility: All peer-reviewed original research articles describing the prevalence of malaria parasitaemia in blood donors with different diagnostic methods were included.Methods: The random-effects model was applied to assess the effects of heterogeneity among the selected studies. Incoherence and heterogeneity between studies were quantified by I2 index and Cochran’s Q test. Publication and population bias was assessed with funnel plots and Egger’s regression asymmetry test. All statistical analyses were performed using Stata (Version 2.7.2).Results: Seventy-one studies from 21 countries, five continents were included in the present systematic review. The median prevalence of malaria parasitaemia among 984,975 asymptomatic healthy blood donors was 10.54%, 5.36% and 0.38% by microscopy, molecular methods (PCR) and rapid diagnostic tests, respectively. The most commonly detected Plasmodium species was P. falciparum.Conclusion: This systematic review demonstrates that compared with other transfusion significant transfusion associated infections especially in sub-Saharan Africa. Future work must aim to understand the clinical significance of transfusion-transmitted malaria in malariaendemic settings. linked infections i.e. HIV, HCV and HBV, transfusion-transmitted malaria is one of the mos
Current developments and future directions in COPD
Get PDFThe European Respiratory Society’s (ERS) journals publish respiratory research and policy documents of the highest quality, offering a platform for the exchange and promotion of scientific knowledge. This new series entitled “Current developments and future directions” aims to critically summarize only some of the most recent, high-quality studies published in the ERS journals, focusing on different disciplines of respiratory medicine. In this first article, focusing on Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death globally, we summarize novel research highlights focusing on the disease’s underlying mechanisms, epidemiology, and management, with the aim to inform and inspire respiratory clinicians and researchers
- …
